Replies to post #277499 on Anavex Life Sciences Corp (AVXL)

[boi568]

If you are proposing to present a radically different paradigm for Alzheimer's Disease at its premier annual conference, you are not getting on the program unless you have a powerful argument. Even then, I suspect, you may not always get on the program.

[Doc328]

CTAD will have a large audience - even if online. Not only is it one of the 2 largest AD meetings, the BIIB Advisory Board with the FDA is actually during the meeting (November 6). This will further increases visibility to press and CFA's. That's why I felt in my post last week that it would be the best place to present for Anavex - though I was uncertain we could meet the LB deadline.

Anavex should release the actual numbers at CTAD. If the delta on the CDR-COA is > 5.5 (What rivastigmine achieved) then I wouldn't be surprised to see AVXL hit $12-$15.

I guess I don't see how the results could be mediocre and be presented there

Many studies with negative and mediocre results are presented at meetings like tihis, often late-breaking.